SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Basic Solution
Basic Solution Spółka z Ograniczoną Odpowiedzialnością
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Basic Solution Spółka z Ograniczoną Odpowiedzialnością
Basic Solution Spółka z Ograniczoną Odpowiedzialnością (KRS 0000617444, NIP 5871706668) is a Polish company, headquartered in Gdańsk, Pomorskie voivodeship. BASIC SOLUTION operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since May 11, 2016.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Main activity
72.19.ZOther research and experimental development on natural sciences and engineering
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Founded
May 11, 2016
10 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
GDAŃSK
POMORSKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
5.0 K PLN
100 shares total
Shareholders
2
shareholders
Board
2 people
Filed years
N/A
Registry entries
21
latest: June 26, 2025
No KPI data - financial statements and valuation are unavailable for this company.
Rate business credibility - Basic Solution.
No ratings
News
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
Latest reporting year
2023
Available years
8
Filing entries
0
20 historical registry entries for Basic Solution
Filing documents submitted (2 documents)
Filing documents submitted (2 documents)
Filing documents submitted (2 documents)
Change in Section 1 (basic data)
GD.VIII NS-REJ.KRS/12484/19/753/ADE
Filing documents submitted (2 documents)
Answers to questions about the company's activity, registered office, identifiers, financial data, capital and control.
BASIC SOLUTION's board has 2 members.
Competing companies or those operating in the same market segment as Basic Solution (in Gdańsk, industry: Research and development).
GDYNIA· Research and development
Revenue 2024: 117.1 M PLN
GDYNIA· Research and development
Revenue 2024: 44.1 M PLN
GDAŃSK· Research and development
Revenue 2024: 41.6 M PLN
GDAŃSK· Research and development
Revenue 2024: 26.2 M PLN
GDAŃSK· Research and development
Revenue 2024: 13.2 M PLN
GDYNIA· Research and development
Revenue 2024: 12.9 M PLN
